GTC
Ghost Tree Capital Portfolio holdings
AUM
$276M
This Quarter Return
+13.98%
1 Year Return
+49.13%
3 Year Return
+198.45%
5 Year Return
+1,783.74%
10 Year Return
+9,775.89%
AUM
$174M
AUM Growth
+$174M
(-16%)
Cap. Flow
-$67M
Cap. Flow
% of AUM
-38.56%
Top 10 Holdings %
Top 10 Hldgs %
45.29%
Holding
75
New
12
Increased
13
Reduced
18
Closed
26
Top Buys
| 1 |
Biohaven
BHVN
|
$11.8M |
| 2 |
Roivant Sciences
ROIV
|
$6.02M |
| 3 |
Sarepta Therapeutics
SRPT
|
$5.79M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
$5.26M |
| 5 |
argenx
ARGX
|
$4.76M |
Top Sells
| 1 |
MoonLake Immunotherapeutics
MLTX
|
$15.1M |
| 2 |
TG Therapeutics
TGTX
|
$12.8M |
| 3 |
Madrigal Pharmaceuticals
MDGL
|
$9.83M |
| 4 |
Ascendis Pharma
ASND
|
$8.19M |
| 5 |
ALPN
Alpine Immune Sciences, Inc. Common Stock
ALPN
|
$7.6M |
Sector Composition
| 1 | Healthcare | 99.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Axsome Therapeutics
AXSM
$6.05B
| $13.1M | 4.29% | 165,000 +55,000 | +50% | +$4.38M |
|
|
2
Biohaven
BHVN
$1.63B
| $11.8M | 3.85% | +275,000 | New | +$11.8M |
|
|
3
Sarepta Therapeutics
SRPT
$1.78B
| $9.64M | 3.15% | 100,000 +60,000 | +150% | +$5.79M |
|
|
AMAM
4
DELISTED
Ambrx Biopharma, Inc. Common Stock
AMAM
| $6.76M | 2.21% | 475,000 -50,000 | -10% | -$712K |
|
|
5
Roivant Sciences
ROIV
$8.15B
| $6.74M | 2.2% | 600,000 +536,000 | +838% | +$6.02M |
|
6
Viridian Therapeutics
VRDN
$1.5B
| $6.53M | 2.14% | 300,000 +25,000 | +9% | +$545K |
|
7
Krystal Biotech
KRYS
$4.27B
| $6.2M | 2.03% | 50,000 -30,000 | -38% | -$3.72M |
|
8
Structure Therapeutics
GPCR
$1.11B
| $6.11M | 2% | 150,000 +95,000 | +173% | +$3.87M |
|
9
Tarsus Pharmaceuticals
TARS
$2.47B
| $6.08M | 1.99% | 300,000 -100,000 | -25% | -$2.03M |
|
|
10
argenx
ARGX
$43.6B
| $5.71M | 1.87% | 15,000 +12,500 | +500% | +$4.76M |
|
|
11
Alnylam Pharmaceuticals
ALNY
$58.5B
| $5.26M | 1.72% | +27,500 | New | +$5.26M |
|
12
BridgeBio Pharma
BBIO
$9.89B
| $5.05M | 1.65% | 125,000 +50,000 | +67% | +$2.02M |
|
|
13
MoonLake Immunotherapeutics
MLTX
$3.54B
| $4.83M | 1.58% | 80,000 -250,000 | -76% | -$15.1M |
|
|
JBIO
14
Jade Biosciences, Inc. Common Stock
JBIO
$258M
| $4.75M | 1.55% | 210,000 +8,803 | +4% | +$199K |
|
15
Soleno Therapeutics
SLNO
$3.6B
| $4.52M | 1.48% | +112,385 | New | +$4.52M |
|
16
Vaxcyte
PCVX
$4B
| $4.4M | 1.44% | 70,000 -70,000 | -50% | -$4.4M |
|
|
17
TG Therapeutics
TGTX
$4.65B
| $4.27M | 1.4% | 250,000 -750,000 | -75% | -$12.8M |
|
18
EyePoint Pharmaceuticals
EYPT
$797M
| $3.81M | 1.25% | 165,000 -160,000 | -49% | -$3.7M |
|
19
Taysha Gene Therapies
TSHA
$797M
| $3.72M | 1.22% | 2,100,000 +775,000 | +58% | +$1.37M |
|
|
DCPH
20
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $3.63M | 1.19% | 225,000 -100,000 | -31% | -$1.61M |
|
21
Savara
SVRA
$567M
| $3.53M | 1.15% | +750,000 | New | +$3.53M |
|
22
Phathom Pharmaceuticals
PHAT
$864M
| $3.52M | 1.15% | 385,241 -9,759 | -2% | -$89.1K |
|
|
23
Madrigal Pharmaceuticals
MDGL
$9.76B
| $3.47M | 1.13% | 15,000 -42,500 | -74% | -$9.83M |
|
24
Cabaletta Bio
CABA
$133M
| $3.41M | 1.11% | +150,000 | New | +$3.41M |
|
25
Replimune Group
REPL
$422M
| $3.37M | 1.1% | +400,000 | New | +$3.37M |
|